Abstract: Provided are a text processing method, a device and a storage medium, relating to a field of computer technology, and especially to a field of artificial intelligence, such as natural language processing and deep learning. The specific implementation scheme includes: performing text processing on first text, by using a text processing acceleration operator; and processing, in parallel and faster, content after the text processing, by using the text processing acceleration operator. Text processing and parallel acceleration are carried out by the text processing acceleration operator, which can improve the speed of text processing.

Abstract: Chlorogenic acid and/or coumaroylquinic acid are employed in preparation of drugs for treating squamous cell carcinoma. Chlorogenic acid or coumaroylquinic acid can effectively treat squamous cell carcinoma. A combination of chlorogenic acid and coumaroylquinic acid can also achieve effective treatment, can yield a synergistic effect, and has excellent application prospect.

Abstract: A pharmaceutical composition includes chlorogenic acid and coumaroylquinic acid. It can be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1/PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid exhibits a synergistic effect, effectuating a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, which may effectively inhibit PD-1/PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.

Abstract: A method for determining the quality of diffusion welding by means of non-destructive testing comprises the steps of determining a testing method, performing batch testing, establishing a relationship, performing a classification of the mechanical performance data of welded joints, performing a classification of quality levels of different welded interfaces, performing a classification of quality levels of the welded joints, and determining quality levels of the welded joints of to-be-tested workpieces.

Abstract: A pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects.

Abstract: Chlorogenic acid or compositions containing chlorogenic acid are used in preparation of a medicament for treating sarcoma. The chlorogenic acid composition includes chlorogenic acid and coumaroyl quinic acid, can effectively treat sarcoma, and has a better therapeutic effect than the chemotherapeutic medicament doxorubicin. The experimental results show that the combination of chlorogenic acid and coumaroylquinic acid can have a synergistic effect.

Abstract: A pharmaceutical composition containing chlorogenic acid is used in the preparation of a medicament for treating pathologic jaundice. In the pharmaceutical composition, chlorogenic acid is used as a main active ingredient, and bifidobacteria and human milk oligosaccharides are used as auxiliary ingredients. The latter can effectively enhance the therapeutic effect of chlorogenic acid for treating pathologic jaundice, thereby reducing the amount thereof. The pharmaceutical composition can effectively reduce the contents of total bilirubin and indirect bilirubin in blood, and provides a new means and choice for pharmacotherapy of pathologic jaundice, especially hemolytic jaundice.

Abstract: Disclosed are an 8-(picolinamide) substituted coumarin compound, and a preparation method therefor and the use thereof, wherein the structure of the 8-(picolinamide) substituted coumarin compound is represented by formula (I), and a ring A is independently selected from a group composed of phenyl, naphthyl and a 5-14 membered aromatic heterocyclyl. The 8-(picolinamide) substituted coumarin compound disclosed in the present application is of a brand-new compound structure and has a strong SIRT2 inhibitory activity, wherein the in-vitro SIRT2 inhibitory activity IC50 of 18 compounds reaches a micromolar level, and the 8-(picolinamide) substituted coumarin compound has a significant protective effect on neuroma cells. Therefore, the compound can be widely used for preparing drugs for treating and/or preventing diseases or conditions related to excessive SIRT2 activity or overexpression of SIRT2, or preparing drugs for treating and/or preventing Parkinsons disease, metabolic diseases and tumors.

Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.

Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.

Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.

Abstract: The present disclosure provides a thin-film transistor and a method for manufacturing the same, an array substrate, and a display device. The thin film transistor of the present disclosure include a plurality of insulating layers, among which at least one insulating layer on the low temperature polysilicon layer comprises organic material, so vias could be formed in the organic material by an exposing and developing process, thereby effectively avoiding the over-etching problem of the low temperature polycrystalline silicon layer caused by dry etching process. By adopting the method for manufacturing the film transistors of the present disclosure, the contact area and uniformity of the drain electrode and the low temperature polysilicon material layer can be increased; the conductivity can be improved; and the production cycle of products can be greatly reduced and thereby improving the equipment capacity.

Abstract: The technology of this application relates to a V2X communication method and an apparatus. The method includes a first network element obtains UE density information of a first area in which target UE is located, and the first network element sends first information to the target UE based on the UE density information, where the first information is used by the target UE to adjust transmit power of a PC5 interface. The method provided in this application can improve V2X communication quality, and further reduce power consumption of UE. In addition, it can also be avoided that primary responsibility of an accident is transferred to a server, and information received by the UE is determined using global information, so that an error can be reduced.

Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.

Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.

Abstract: A communication mode selection method includes transmitting, in a first communication mode, a vehicle-to-everything (V2X) service between a leading vehicle and a following vehicle that are in a vehicle platoon, obtaining, signal quality of the first communication mode, when the signal quality of the first communication mode meets a first preset condition, sending, a configuration instruction to the following vehicle, where the configuration instruction is used to instruct the following vehicle to communicate with the leading vehicle in a second communication mode, where the second communication mode is a communication mode in which a network device performs forwarding.

Abstract: A vehicle warning method, to avoid misjudgment caused by factors such as map precision and lane infringement of a vehicle, thereby improving warning accuracy. The method includes: A vehicle-to-everything V2X device receives a V2X message corresponding to a first vehicle. The V2X device determines, based on the V2X message, whether the first vehicle is in a warning area. The warning area is determined based on vehicle information of a second vehicle. The vehicle information includes at least position information of the second vehicle and a vehicle size of the second vehicle. The V2X device outputs warning information corresponding to the first vehicle to the second vehicle.

Abstract: A drug combination for treatment of amyotrophic lateral sclerosis includes chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium, as well as pharmaceutically acceptable carriers, in which chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium are unit preparations having same or different specifications, that are simultaneously or separately administrated. The combination of chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium shows a synergistic effect on amyotrophic lateral sclerosis, thus provides a combination with excellent therapeutic effect on amyotrophic lateral sclerosis, which delays the progression of amyotrophic lateral sclerosis.

Abstract: A method includes obtaining, by a control platform, request information, where the request information carries an identifier of user equipment (UE) and an identifier of a vehicle-mounted device, and sending indication information to the UE based on the request information, where the indication information instructs the UE to disable or enable a vehicle-to-pedestrian (V2P) function to forbid or allow the UE to transmit a V2P message.

Abstract: A communication mode switching method, a network side device, and a terminal device includes a communication mode of the second vehicle to everything (V2X) service is switched from a first communication mode to the second communication mode for scheduling a first V2X service of a radio resource to be transmitted using the first communication mode.